Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (136)	10/16/2000 11:08:04 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 539

While I believe that NMR technique will add into protein-smal molecules interaction studies, this sound like prime rate BS, imho. New NMR-based Technology to Shorten Drug Discovery Chemistry From Years to Weeks Triad Therapeutics Reports Proof of Principle of IOPE(TM) Proprietary Drug Discovery Platform at BioPartnering Europe Conference LONDON, Oct. 16 /PRNewswire/ -- Triad Therapeutics, Inc., introduced IOPE(TM) today, its proprietary drug discovery platform guided by NMR spectroscopy, which is expected to shorten the drug discovery process of generating potent and specific lead compounds from 2-5 years to less than 2 months. The Company reported at the BioPartnering Europe Conference that proof of principle has been achieved for IOPE seven months ahead of schedule. "The number of drug targets in the human genome is expected to increase from about 500 to 5000 as the result of genomics research. Targets, however, do not cure disease -- drugs do," said Stephen M. Coutts, Ph.D., President of Triad Therapeutics. "Triad's IOPE platform technology allows us to accelerate drug discovery for existing and post-genomics targets. With IOPE, we can design drug collections for entire families of genes even before a disease link with a particular gene is discovered. Then as new gene targets are identified, the appropriate drug candidates at Triad can be screened to produce a highly potent and specific drug lead within a matter of weeks -- not the years associated with current drug discovery technologies." IOPE, or Integrated Object-Oriented PharmacoEngineering, employs the proven technology of nuclear magnetic resonance (NMR) spectroscopy to quickly gather structural information on key gene families and the proteins they encode. The structural data are used to guide the construction of highly focused compound collections that are biased against those gene families. By screening new targets in the appropriate gene families against the biased compound collections, the Company expects to produce highly potent and specific leads within weeks after being presented a new target. Triad recently used IOPE to produce several nanomolar hits (between 25 and 100 nM) from a new drug scaffold by synthesizing a collection of fewer than 200 compounds. "Because IOPE uses an object-oriented approach to assemble chemical modules like building blocks into drug compounds," Dr. Coutts explained, "our collections have the highly desirable feature of being reusable. They can be used again and again for screening as new disease targets are discovered. This is a very different approach from traditional drug discovery in which drug design starts only after the target is identified." Triad Therapeutics was founded in 1998 by Dr. Coutts, Daniel Sem, Ph.D., as well as John Freund of Skyline Ventures, and completed its first round of financing in mid-1999. The Company recently initiated its Series B round of financing. "Our business strategy going forward is of a dual nature," said Dr. Coutts. "We will not only provide lead compounds to customers within the biotech and pharmaceutical arena, but will also develop our own leads into clinical candidates." Triad Therapeutics, Inc., headquartered in San Diego, California, is a biopharmaceutical company focused on rapidly generating highly potent and specific drug candidates through the use of IOPE(TM) (Integrated Object-Oriented PharmacoEngineering), a proprietary, structure-based discovery platform. Triad is leveraging genomics to speed drug discovery by constructing highly focused collections of small molecule inhibitors that are specific for key gene families traditionally rich in drug targets. As part of a dual business strategy, Triad will provide high-affinity, nanomolar chemical lead compounds to the pharmaceutical and biotechnology industries. Triad will also develop its own leads into clinical candidates. For more information on Triad Therapeutics, Inc., please visit our website at triadthera.com. IOPE(TM) is a trademark of Triad Therapeutics, Inc.